All In Biotech

Drug Trial Radar · NCT06967610

Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Jul 15, 2025

Primary completion

Jun 1, 2031

Study completion Jun 1, 2033

Sponsor

Lead sponsor
M.D. Anderson Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Eli Lilly and Company
First posted
May 13, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To learn if the drug combination pirtobrutinib, venetoclax, and obinutuzumab can help to control relapsed CLL/SLL.

Conditions

  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Leukemia (SLL)

Interventions

  • PirtobrutinibDrug

    Given PO 200mg daily

  • VenetoclaxDrug

    Given PO daily

  • ObinutuzumabDrug

    Given IV 100mg day 1, 900 mg day 2, 100mg days 8, 15

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and adverse eventsTime frame: Through study completion; an average of 1 year.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.